Sign in

CIK 0001590877

  • Non-accelerated filer
  • Smaller reporting company

REGENXBIO Inc.

Sign in to watch
Ticker
RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
471851754
Phone
+1 240-552-8181
Business address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Former names
ReGenX Biosciences, LLC
Open-market buys, last 90 days
$949,381
in 1 filing
Open-market sales, last 90 days
$0
in 0 filings

Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Ciongoli Gregory Austin +$949K Director 1 filing

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2019-02-15 Mills Kenneth T. President and CEO Sale −3,522 $47.30 $167K 254,066
2019-02-15 Mills Kenneth T. President and CEO Sale −8,066 $47.84 $386K 246,000
2019-02-14 Mills Kenneth T. President and CEO Exercise or conversion +15,000 $0.85 $13K 261,000
2019-02-14 Mills Kenneth T. President and CEO Exercise or conversion · Employee Stock Option (Right to Buy) −15,000 174,670
2019-02-07 Vasista Vittal Chief Financial Officer Exercise or conversion +120,000 $0.85 $102K 242,283
2019-02-07 Vasista Vittal Chief Financial Officer Exercise or conversion · Employee Stock Option (Right to Buy) −120,000 84,900
2019-02-05 Simpson Curran SVP, Product Development & CTO Exercise or conversion +8,450 $35.80 $303K 47,950
2019-02-05 Simpson Curran SVP, Product Development & CTO Exercise or conversion +32,882 $22.00 $723K 80,832
2019-02-05 Simpson Curran SVP, Product Development & CTO Exercise or conversion +1,875 $19.50 $37K 82,707
2019-02-05 Simpson Curran SVP, Product Development & CTO Exercise or conversion +625 $13.09 $8K 83,332
2019-02-05 Simpson Curran SVP, Product Development & CTO Sale −43,832 $50.08 $2.2M 39,500
2019-02-05 Simpson Curran SVP, Product Development & CTO Exercise or conversion · Stock Option (Right to Buy) −8,450 46,550
2019-02-05 Simpson Curran SVP, Product Development & CTO Exercise or conversion · Stock Option (Right to Buy) −32,882 43,219
2019-02-05 Simpson Curran SVP, Product Development & CTO Exercise or conversion · Stock Option (Right to Buy) −1,875 15,000
2019-02-05 Simpson Curran SVP, Product Development & CTO Exercise or conversion · Stock Option (Right to Buy) −625 2,708
2019-02-01 Mills Kenneth T. President and CEO Exercise or conversion +45,000 $0.85 $38K 246,000
2019-02-01 Mills Kenneth T. President and CEO Exercise or conversion · Employee Stock Option (Right to Buy) −45,000 189,670
2019-01-15 Mills Kenneth T. President and CEO Sale −11,860 $43.70 $518K 204,140
2019-01-15 Mills Kenneth T. President and CEO Sale −3,140 $44.40 $139K 201,000
2019-01-03 Christmas Patrick J. SVP, General Counsel Grant or award · Stock Option (Right to Buy) +45,000 45,000

Page 30 of 43 · 852 trades